What this means
This is a trial that has not reported results yet. It will study BGE-102 and check blood markers, including a marker of inflammation called hsCRP.
Plain-English summary written by an AI model from the registry listing.
- Status
- Active not recruiting
- Who can join
- Ages 18 and over
- Where
- 17 sites, including Arizona, Arkansas, Florida
The science
- Registered title
- A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors
- Trial ID
- NCT07656727 ↗
- Phase
- PHASE 2
- Study type
- interventional
- Conditions
- Obesity and Cardiovascular Risk
- What is tested
- Oral BGE-102, Oral Placebo Matching BGE-102
- Sponsor
- BioAge Labs, Inc.
- Ages
- 18 Years to no maximum
- Dates
- First posted Jun 18, 2026 · updated Sep 10, 2026
Registry summary
The purpose of this study is to learn about the effects of BGE-102 on blood biomarkers including hsCRP, which is a lab value used to measure inflammation. BGE-102 decreases inflammation which may improve obesity and cardiovascular health. Participants will receive either BGE-102 or placebo. This study will be checking safety and tolerability of BGE-102.
Sites (17)
- Site 108, Chandler, Arizona, United States
- Site 115, Peoria, Arizona, United States
- Site 110, Tucson, Arizona, United States
- Site 100, Rogers, Arkansas, United States
- Site 109, Maitland, Florida, United States
- Site 102, Miami, Florida, United States
- Site 104, Port Orange, Florida, United States
- Site 103, Lexington, Kentucky, United States
- Site 106, Rockville, Maryland, United States
- Site 113, Kansas City, Missouri, United States
- Site 116, Las Vegas, Nevada, United States
- Site 111, Hartsdale, New York, United States
- Site 112, Austin, Texas, United States
- Site 114, Dallas, Texas, United States
- Site 101, San Antonio, Texas, United States
And 2 more on the listing.
More aging trials in these states
Arizona · Arkansas · Florida · Kentucky · Maryland · Missouri · Nevada · New York · Texas